Lenalidomide Sandoz (Lenalidomide)

Lenalidomide binds to cereblon, a component of the CRL4‑CRBN E3 ubiquitin ligase complex, changing the complex’s substrate preference. This triggers the ubiquitination and subsequent degradation of transcription factors Ikaros and Aiolos, which suppresses malignant plasma‑cell growth, inhibits new blood‑vessel formation, and enhances immune‑mediated tumor cell killing.

The specific dose of Lenalidomide Sandoz is individualized and must be determined by a qualified prescriber. Dosing depends on the approved indication, patient’s renal function, prior therapies, and overall clinical status, and it is adjusted according to laboratory monitoring and treatment response.

Lenalidomide is classified as Pregnancy Category X, indicating it is contraindicated during pregnancy because of proven teratogenic risk. Women of child‑bearing potential must use effective contraception. The drug is also not recommended while breastfeeding, as it may be excreted in milk and could harm the infant.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Lenalidomide Sandoz. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Lenalidomide and thalidomide belong to the same immunomodulatory drug class, but lenalidomide generally offers a more favorable safety profile, especially regarding peripheral neuropathy. Both agents share a similar mechanism of cereblon binding, yet lenalidomide is often preferred for patients who require stronger anti‑angiogenic activity and a lower incidence of certain toxicities.

Store Lenalidomide Sandoz tablets at temperatures below 25 °C, in the original container, and protect them from moisture and direct light. Keep the product out of reach of children and avoid crushing or splitting tablets unless directed by a healthcare professional.

Lenalidomide Sandoz is taken orally as a whole tablet, usually once daily on a schedule defined by the prescribing physician. It may be taken with or without food, but patients should follow any specific instructions regarding timing relative to meals and other medications.

The most critical risks include severe neutropenia that can lead to life‑threatening infections, venous thromboembolism (blood clots), secondary primary malignancies, and rare hypersensitivity reactions such as Stevens‑Johnson syndrome. Patients should be monitored closely for signs of infection, unexplained bruising, or allergic symptoms and report them immediately.

Lenalidomide Sandoz should not be used by pregnant women, nursing mothers, or individuals with known hypersensitivity to lenalidomide or any component of the formulation. It is also contraindicated in patients with uncontrolled active infections or those who cannot safely receive anticoagulation when a high thrombotic risk is present.